Premium
The impact of the COVID‐19 pandemic on the Ontario Cervical Screening Program, colposcopy and treatment services in Ontario, Canada: a population‐based study
Author(s) -
Meggetto O,
Jembere N,
Gao J,
Walker MJ,
Rey M,
Rabeneck L,
Murphy KJ,
Kupets R
Publication year - 2021
Publication title -
bjog: an international journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.157
H-Index - 164
eISSN - 1471-0528
pISSN - 1470-0328
DOI - 10.1111/1471-0528.16741
Subject(s) - colposcopy , medicine , cervical screening , pandemic , cervical cancer , population , cytology , cervix , gynecology , obstetrics , cervical cancer screening , covid-19 , cancer , environmental health , pathology , disease , infectious disease (medical specialty)
Objective To describe the immediate impact of the COVID‐19 pandemic on cervical screening, colposcopy and treatment volumes in Ontario, Canada. Design Population‐based retrospective observational study. Setting Ontario, Canada. Population People with a cervix age of 21–69 years who completed at least one cervical screening cytology test, colposcopy or treatment procedure for cervical dysplasia between January 2019 and August 2020. Methods Administrative databases were used to compare cervical screening cytology, colposcopy and treatment procedure volumes before (historical comparator) and during the first 6 months of the COVID‐19 pandemic (March–August 2020). Main outcome measures Changes in cervical screening cytology, colposcopy and treatment volumes; individuals with high‐grade cytology awaiting colposcopy. Results During the first 6 months of the COVID‐19 pandemic, the monthly average number of cervical screening cytology tests, colposcopies and treatments decreased by 63.8% (range: −92.3 to −41.0%), 39.7% (range: −75.1 to −14.3%) and 31.1% (range: −43.5 to −23.6%), respectively, when compared with the corresponding months in 2019. Between March and August 2020, on average 292 (−51.0%) fewer high‐grade cytological abnormalities were detected through screening each month. As of August 2020, 1159 (29.2%) individuals with high‐grade screening cytology were awaiting follow‐up colposcopy. Conclusions The COVID‐19 pandemic has had a substantial impact on key cervical screening and follow‐up services in Ontario. As the pandemic continues, ongoing monitoring of service utilisation to inform system response and recovery is required. Future efforts to understand the impact of COVID‐19‐related disruptions on cervical cancer outcomes will be needed. Tweetable abstract COVID‐19 has had a substantial impact on cervical screening and follow‐up services in Ontario, Canada.